Reperfusion failure despite recanalization in stroke: New translational evidence

Amki, Mohamad El; Wegener, Susanne

Abstract: Current treatment for acute ischemic stroke aims at recanalizing the occluded blood vessel to reperfuse ischemic brain tissue. Clot removal can be achieved pharmacologically with a thrombolytic drug, such as recombinant tissue plasminogen activator, or with mechanical thrombectomy. However, reopening the occluded vessel does not guarantee full tissue reperfusion, which has been referred to as reperfusion failure. When it occurs, reperfusion failure significantly attenuates the beneficial effect of recanalization therapy and severely affects functional recovery of stroke patients. The mechanisms of reperfusion failure are somewhat complex and not fully understood. Briefly, after stroke, capillaries show stalls, constriction and luminal narrowing, being crowded with neutrophils, and fibrin–platelet deposits. Furthermore, after recanalization in stroke patients, a primary clot can break, dislodge, and occlude distal arterial branches further downstream. In this review, we highlight a rodent model that allows studying the pathophysiological mechanisms underlying reperfusion failure after stroke. We also describe the vascular and intravascular changes involved in reperfusion, which may provide relevant therapeutic targets for improving treatment of stroke patients.

DOI: https://doi.org/10.1177/2514183x211007137

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-209900
Journal Article
Published Version

The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) License.

Originally published at:
Amki, Mohamad El; Wegener, Susanne (2021). Reperfusion failure despite recanalization in stroke: New translational evidence. Clinical and Translational Neuroscience, 5(1):online.
DOI: https://doi.org/10.1177/2514183x211007137
Reperfusion failure despite recanalization in stroke: New translational evidence

Mohamad El Amki and Susanne Wegener

Abstract
Current treatment for acute ischemic stroke aims at recanalizing the occluded blood vessel to reperfuse ischemic brain tissue. Clot removal can be achieved pharmacologically with a thrombolytic drug, such as recombinant tissue plasminogen activator, or with mechanical thrombectomy. However, reopening the occluded vessel does not guarantee full tissue reperfusion, which has been referred to as reperfusion failure. When it occurs, reperfusion failure significantly attenuates the beneficial effect of recanalization therapy and severely affects functional recovery of stroke patients. The mechanisms of reperfusion failure are somewhat complex and not fully understood. Briefly, after stroke, capillaries show stalls, constriction and luminal narrowing, being crowded with neutrophils, and fibrin–platelet deposits. Furthermore, after recanalization in stroke patients, a primary clot can break, dislodge, and occlude distal arterial branches further downstream. In this review, we highlight a rodent model that allows studying the pathophysiological mechanisms underlying reperfusion failure after stroke. We also describe the vascular and intravascular changes involved in reperfusion, which may provide relevant therapeutic targets for improving treatment of stroke patients.

Keywords
Stroke, ischemia, thrombin model, reperfusion, capillary stalls

Introduction
Stroke is a major global health problem in our society, particularly due to many people affected from lifelong disabilities. In the majority of cases, stroke is ischemic, caused by a clot occluding an artery supplying the brain. Because of the occlusion, blood flow to the brain suddenly stops or severely diminishes in parts of the vascular system. In the infarct “core,” flow reduction is most severe, while the “penumbra” surrounding the core receives residual blood supply, mainly via vascular collaterals. In the core, oxygen and glucose deprivation lead to irreversible necrotic cell death within minutes while in the penumbra, tissue remains viable for several hours. Various endogenous mechanisms, including excitotoxicity, oxidative damage, and inflammation contribute to the progression of neuronal death. Stroke research focused on developing neuroprotective drugs to reduce the extent of neuronal damage in the penumbra, but apart from recanalization therapies, no therapeutic agent has clearly demonstrated neuroprotection and reliable preservation of neurological functions in the clinical setting. One reason for this problem could be that after stroke, damage is not restricted to neurons only, but affects vascular cells as well, which so far was largely neglected. Recovery of vascular function and full restoration of blood supply after stroke are likely to be critical prerequisites for neuroplasticity and favorable clinical outcome.

The mainstay of contemporary acute ischemic stroke treatment is timely removal of the occlusive clot with intravenous thrombolysis and endovascular thrombectomy.
Many patients with acute ischemic stroke receive recanalization therapies; however, more than 50% of patients with large vessel occlusion stroke show no improvement or even worsening of clinical status despite successful thrombectomy.

Such futile recanalization (or reperfusion failure) is attributable to a failure of regaining normal macro- and/or microvascular function despite recanalization of the occluded vessel. Today, increasing evidence suggests that—similar to ischemic heart disease—the vascular bed during and after stroke becomes dysfunctional, and removing the occlusive clot is not enough to recover a proper vascular function. Here we will summarize the mechanisms suggested to result in reperfusion failure after stroke.

**Studying reperfusion failure: The thrombin stroke model**

There is a paucity of rodent models to study ischemic stroke in the middle cerebral artery territory, which can be categorized into models of permanent versus transient vessel occlusion. More recently, experimental research has adopted rodent models to incorporate vascular risk factors and comorbidities, including age, hypertension, or small vessel disease.

To study reperfusion failure, transient middle cerebral artery occlusion (MCAO) by a filament for 30 or 60 min is a widely applied technique, which is easily performed and well characterized in mice and rats. However, direct visualization of the occlusion site is not possible, which results in considerable lesion variability due to slight differences in vascular anatomy. Furthermore, with the silicone-covered microfilament, the real interaction of a clot with vessel endothelium, and more importantly, clot resolution by thrombolysis is not reproduced. In addition, since the filament is inserted mechanically through a cut into the common carotid or external carotid artery, large vessels have to be permanently sutured after filament retraction to prevent bleeding, altering the natural collateral network.

The thrombin model of MCAO overcomes these drawbacks and creates the unique opportunity to mimic clot formation and intravenous thrombolysis in rodents. Albeit technically more challenging than filament occlusion models, it is very reproducible in different laboratories. In brief, thrombin is injected into the distal middle cerebral artery (MCA)-M2 segment using a micropipette, so that a clot is formed in situ, which can be directly visualized (Figure 1). At any desired time,
Thrombolysis is initiated by infusion of tissue plasminogen activator (tPA) through the tail vein. If early treatment time windows are targeted, tPA infusion is started at around 30 min, which usually achieves partial or complete clot resolution. If effects of late thrombolysis are the focus of the study, tPA treatment is started at around 4 h. The model has provided highly valuable insights into efficacy of early/late thrombolysis and has revealed that despite complete clot resolution, cortical reperfusion of the middle cerebral artery (MCA) territory is far from complete, thereby confirming reperfusion failure (see Figure 1(b) and the literature). In vivo imaging allows observation of the clot dissolution and different pathophysiological processes involved (Figure 1(c)). Specific staining techniques inform about the composition of cells and particles within the imaged vessels, as well as type of vascular or perivascular structures.

**Mechanisms of reperfusion failure after stroke**

The structural integrity of the brain vasculature is a major determinant of the local metabolic supply. The brain vasculature is anatomically and functionally compartmentalized into arteries, capillaries, and veins. The cortex receives its blood supply via pial arteries, which diverge into arterioles and eventually end in the capillary network. Proper blood flow in capillaries is crucial for the brain due to their role in maintaining the exchange of oxygen, nutrients, and waste between tissue and blood. Adequate reperfusion requires the coordination between all vascular compartments. Blood flow is regulated by specialized cell types located within vessels: smooth muscle cells and endothelial cells (ECs) in large vessels and ECs and pericytes in capillaries. In fact, there is accumulating clinical and experimental evidence that post-stroke vascular and hemodynamic impairments are due to alterations in different components: intravascular components (distal embolization, microclots, and capillary stalls with neutrophils) and vascular components (large vessels or capillary constriction; see Figure 2).

**Microvascular occlusion with microclots (local thrombosis and distal embolism)**

Microvascular occlusion by clot material is regarded as one of the key mechanisms contributing to microcirculatory...
failure after stroke. Microvascular occlusion may be triggered by embolic fragments from the original proximal thrombus or by local (micro)-thrombosis formed in situ by local platelet activation. The length, density, and composition of a large artery clot depends on stroke etiology. In fact, during clot retrieval, there is a risk of generating small clot debris that may dislodge and migrate, causing downstream circulatory arrest. Clot migration occurs more often in erythrocyte-rich clots and less often in fibrin-rich clots. However, the occurrence, dynamics, and effects of clot migration need further experimental and clinical investigation.

Microclots could also result from the endovascular clot retrieval procedure per se, when endothelial erosion activates the clotting cascade. Microclots have been found in brain microvessels of stroke patients who died within a month after the stroke onset. Cerebral microthrombi usually consist of aggregated platelets and fibrin, sometimes mixed with leukocytes and may even extend into the venous system. Based on these findings, it was suggested that reducing microvascular clogging by antiplatelet drugs or fibrin inhibitors restores microcirculation, reduces no-reflow, and improves stroke outcome. For example, cilostazol, a phosphodiesterase inhibitor acting as an antiplatelet agent, reduced microvascular dysfunction in a model of stroke. Administration of a direct thrombin inhibitor, argatroban, was shown to enhance recanalization rates induced by t-PA. Some of these strategies are currently in clinical trials, such as the combination of argatroban with thrombolysis.

**Capillary stalls with neutrophils**

Previous studies in patients with stroke demonstrated that the number of circulating neutrophils rises within the first hours and that this increase is proportional to stroke severity and functional impairment. Within the healthy capillary network, neutrophils appear to flow smoothly without rotation and without margination. However, in diseases such as stroke and Alzheimer’s disease, neutrophils may get stuck in capillaries and disturb flow, enhancing tissue injury. In stroke, despite reopening of the occluded MCA, capillary stalls occur in the core of the infarction as well as the penumbral region. By imaging flow in cerebral capillaries using two-photon imaging, we recently observed that capillary stalls after stroke were caused by neutrophils getting stuck in the distal capillary segments (Figure 3). Remarkably, depletion of circulating neutrophils using an anti-Ly6G antibody led to a release of capillary stalls and restoration of microvascular circulation.
perfusion. This resulted in an improved neurological outcome and did not aggravate adverse outcomes such as haemorrhages.12 What causes neutrophils to perturb capillary flow? Hemodynamic factors (slow flow), ischemia-induced alterations in the mural cells (ECs and pericytes), and their interaction with the blood cells (adhesion molecules) might be involved. While neutrophil depletion is not a feasible stroke treatment, knowledge about the factors inducing neutrophil clogging of capillaries may reveal new promising therapeutic strategies.

**Capillary constriction and the role of pericytes**

Pericytes are specialized mural cell types located within capillaries that play a crucial role in regulation of the vascular tone.39 Despite some controversy regarding the contribution of pericytes compared to arteriolar and venular smooth muscle cells in regulation of cerebral blood flow during ischemia,40 pericytes seem to be particularly sensitive to ischemia, and their death causes irreversible capillary constriction “rigor.”42 This leads to breakdown of the blood brain barrier, which likely contributes to the ingress of peripheral inflammatory cells to the brain parenchyma and increased risk of haemorrhage41 when spontaneous or therapeutic reperfusion occurs. Furthermore, damage to the endothelium may impair release of vasoactive substances such as nitric oxide and endothelium-derived relaxing factor, further aggravating pericyte contraction. Pericyte proliferation and recruitment are tightly regulated by ECs, but the mechanisms of interaction between these mural cells are still an area of active investigation.42 Astrocytes also contribute to the generation of vascular tone and mediate neurovascular signaling to capillary pericytes.43 Several mechanisms of astrocytic synthesis of vasodilators such as prostaglandin E2, epoxyeicosatrienoic acids, and K+ have been described.44,45 However, the precise role of astrocytes in regulating blood flow under pathological conditions, including stroke and Alzheimer’s disease, remains an open question.

**Large vessel constriction**

Stroke is associated with structural and functional alterations in large vessels just downstream of the vessel occlusion, which can present as vascular wall thickening and endothelial dysfunction. Constrictions of cerebral arterioles, resulting in a significant decrease in cerebral blood flow, have been reported in MCAO models46 and are likely to contribute to incomplete reperfusion after stroke. Mechanisms contributing to such pathological constriction and vascular dysfunction include an increase in arterial stiffness, impaired vascular reactivity, and reduced endothelial nitric oxide synthase (eNOS) phosphorylation.41 Stroke affects the whole neurovascular unit, and thus astrocytes, microglia, and neurons in addition to vascular ECs and pericytes. Therefore, multiple regulatory levels exist, and their interplay is complex.41 However, own preliminary data and observations from other groups indicate that vascular collaterals are key players in diminishing pressure gradients and enabling nutrient supply to facilitate pathological constriction of distal arteriolar vessel segments in stroke.47 Therefore, support of collateral flow and/or vascular protection through enhancement of endothelial function or prolongation of EC survival could be a very efficient approach for stroke protection.

**Conclusion**

There is ample evidence for the detrimental effects of reperfusion failure after recanalization in stroke patients. With more aggressive recanalization approaches, including patients with symptom onset >12 h and large infarct core, reperfusion failure will become even more prevalent. To study this important obstacle to clinical recovery from stroke, sophisticated rodent models are now available. Combined with in vivo imaging, these models have revealed key components that could be therapeutic targets to counteract reperfusion failure. Importantly, these targets go beyond earlier neuroprotection-centered approaches toward a more integrated view that incorporates vascular structures and their interaction with the neurovascular unit. These models offer the unique chance for a successful translation of knowledge into clinical practice.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the UZH Clinical Research Priority Program (CRPP) stroke, by the Swiss Heart foundation (FF19035) and by the Swiss National Science Foundation PP00P3_170683.

**ORCID iD**

Susanne Wegener https://orcid.org/0000-0003-4369-7023

**References**

1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation 2019; 139(10): e56–e66.
2. Heiss WD. The ischemic penumbra: correlates in imaging and implications for treatment of ischemic stroke. The Johann Jacob Wepfer award 2011. Cerebrovasc Dis 2011; 32(4): 307–320.
3. Astrup J, Sjesjo BK and Symon L. Thresholds in cerebral ischemia—the ischemic penumbra. Stroke 1981; 12(6): 723–725.
4. Dirnagl U, Iadecola C and Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22(9): 391–397.
5. Dimagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006; 26(12): 1465–1478.
6. Zille M, Ihksan M, Jiang Y, et al. The impact of endothelial cell death in the brain and its role after stroke: a systematic review. Cell Stress 2019; 3(11): 330–347.
7. El Amki M and Wegener S. Improving cerebral blood flow after arterial recanalization: a novel therapeutic strategy in stroke. Int J Mol Sci 2017; 18(12): 2669.
8. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016; 387(10029): 1723–1731.
9. Campbell BCV, De Silva DA, Macleod MR, et al. Ischaemic stroke. Nat Rev Dis Primers 2019; 5(1): 70.
10. Espinosa de Rueda M, Parrilla G, Manzano-Fernandez S, et al. Combined multimodal computed tomography score correlates with futile recanalization after thrombectomy in patients with acute stroke. Stroke 2015; 46(9): 2517–2522.
11. Granger DN and Kvetys PR. Reperfusion therapy—What’s with the obstructed, leaky and broken capillaries? Pathophysiology 2017; 24(4): 213–228.
12. El Amki M, Gluck C, Binder N, et al. Neutrophils obstructing brain capillaries are a major cause of no-reflow in ischemic stroke. Cell Rep 2020; 33(2): 108260.
13. Mergenthaler P and Meisel A. Do stroke models model capillary reflow despite successful opening of an occluded cerebral artery. Nat Med 2009; 15(9): 1031–1037.
23. Knowland D, Arac A, Sekiguchi KJ, et al. Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. Neuron 2014; 82(3): 603–617.
24. Erdener SE, Tang J, Kilic K, et al. Dynamic capillary stalls in reperfused ischemic penumbra contribute to injury: a hyperacute role for neutrophils in persistent traffic jams. J Cereb Blood Flow Metab 2020: 41: 236–252.
25. Kaeasmacher J, Bocckl-Behrens T, Simon S, et al. Risk of thrombus fragmentation during endovascular stroke treatment. AJNR Am J Neuroradiol 2017; 38(5): 991–998.
26. Heye N, Paetzold C, Steinberg R, et al. The topography of microthrombi in ischemic brain infarct. Acta Neurol Scand 1992; 86(5): 450–454.
27. Fitzgerald S, Rossi R, Mereuta OM, et al. Per-pass analysis of acute ischaemic stroke clots: impact of stroke etiology on extracted clot area and histological composition. J Neurointerv Surg 2020. DOI: 10.1136/neurintsurg-2020-016966.
28. Deng J, Zhang Y, He G, et al. Arterial wall injury and miRNA expression induced by stent retriever thrombectomy under ste-noitic conditions in a dog model. J Neurointerv Surg. Epub ahead of print 28 August. DOI: 10.1136/neurintsurg-2020-016347.
29. Heye N and Cervos-Navarro J. Microthromboemboli in acute infarcts: analysis of 40 autopsy cases. Stroke 1996; 27(3): 431–434.
30. Desilis JP, Syvannarath V, Di Meglio L, et al. Downstream microvascular thrombosis in cortical venules is an early response to proximal cerebral arterial occlusion. J Am Heart Assoc 2018; 7(5): e007804.
31. Desilis JP, Loyau S, Syvannarath V, et al. Alteplase reduces downstream microvascular thrombosis and improves the benefit of large artery recanalization in stroke. Stroke 2015; 46(11): 3241–3248.
32. Fukuoka T, Hayashi T, Hirayama M, et al. Cilostazol inhibits platelet-endothelial cell interaction in murine microvessels after transient bilateral common carotid artery occlusion. J Stroke Cerebrovasc Dis 2014; 23(5): 1056–1061.
33. Lyden P, Pereira B, Chen B, et al. Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models. Stroke 2014; 45(3): 896–899.
34. Deeds SI, Barreto A, Elm J, et al. The multiamtor optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: rationale and methods. Int J Stroke. Epub ahead of print 9 December 2020. DOI: 10.1177/1747493020978345.
35. Malhotra K, Goyal N, Chang JJ, et al. Differential leukocyte counts on admission predict outcomes in patients with acute ischaemic stroke treated with intravenous thrombolysis. Eur J Neurol 2018; 25(12): 1417–1424.
36. Chen J, Zhang Z, Chen L, et al. Correlation of changes in leukocyte levels 24 hours after intravenous thrombolysis with prognosis in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis 2018; 27(10): 2857–2862.
37. Doerschuk CM, Beyers N, Coxson HO, et al. Comparison of neutrophil and capillary diameters and their relation to
neutrophil sequestration in the lung. *J Appl Physiol (1985)* 1993; 74(6): 3040–3045.

38. Cruz Hernandez JC, Bracko O, Kersbergen CJ, et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models. *Nat Neurosci* 2019; 22(3): 413–420.

39. Brown LS, Foster CG, Courtney JM, et al. Pericytes and neurovascular function in the healthy and diseased brain. *Front Cell Neurosci* 2019; 13: 282.

40. Hill RA, Tong L, Yuan P, et al. Regional blood flow in the normal and ischemic brain is controlled by arteriolar smooth muscle cell contractility and not by capillary pericytes. *Neuron* 2015; 87(1): 95–110.

41. Freitas-Andrade M, Raman-Nair J and Lacoste B. Structural and functional remodeling of the brain vasculature following stroke. *Front Physiol* 2020; 11: 948.

42. Smart N. Understanding the recruitment process: how endothelial cells control pericyte proliferation, invasion, and recruitment. *Arterioscler Thromb Vasc Biol* 2020; 40(11): 2564–2565.

43. Mishra A, Reynolds JP, Chen Y, et al. Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles. *Nat Neurosci.* 2016; 19(12): 1619–1627.

44. Liu LR, Liu JC, Bao JS, et al. Interaction of microglia and astrocytes in the neurovascular unit. *Front Immunol* 2020; 11: 1024.

45. MacVicar BA and Newman EA. Astrocyte regulation of blood flow in the brain. *Cold Spring Harb Perspect Biol* 2015; 7(5): a020388.

46. Kanoke A, Akamatsu Y, Nishijima Y, et al. The impact of native leptomeningeal collateralization on rapid blood flow recruitment following ischemic stroke. *J Cereb Blood Flow Metab* 2020; 40(11): 2165–2178.

47. Ma J, Ma Y, Dong B, et al. Prevention of the collapse of pial collaterals by remote ischemic perconditioning during acute ischemic stroke. *J Cereb Blood Flow Metab* 2017; 37(8): 3001–3014.